BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/23/2022 2:39:01 PM | Browse: 354 | Download: 1004
 |
Received |
|
2021-08-08 06:55 |
|
Peer-Review Started |
|
2021-08-08 06:59 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-11-11 08:37 |
|
Revised |
|
2021-11-18 15:15 |
|
Second Decision |
|
2022-05-24 03:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-28 07:15 |
|
Articles in Press |
|
2022-05-28 07:15 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-04-23 11:44 |
|
Typeset the Manuscript |
|
2022-05-30 09:21 |
|
Publish the Manuscript Online |
|
2022-06-23 14:39 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jing Hong Loo, Wen Xin Flora Xu, Jun Teck Low, Wei Xuan Tay, Le Shaun Ang, Yew Chong Tam, Prem Harichander Thurairajah, Rahul Kumar and Yu Jun Wong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Nurturing Clinician Scientist Scheme (NCCS) award by SingHealth Duke-NUS Academic Medical Centre and National Medical Research Council Singapore |
|
|
| Corresponding Author |
Yu Jun Wong, FRCP, MD, Consultant Physician-Scientist, Department of Gastroenterology and Hepatology, Changi General Hospital, Singhealth, 2, Simei Street 3, Singapore 529889, Singapore. eugene.wong.y.j@singhealth.com.sg |
| Key Words |
Direct-acting antiviral; Hepatitis C; Cirrhosis; Sofosbuvir/velpatasvir |
| Core Tip |
Ribavirin (RBV) as routine add-on therapy was not associated with higher sustained virological response in genotype 3 (GT3) compensated cirrhosis patients receiving sofosbuvir/velpatasvir (SOF/VEL), except in the subgroup of patients with baseline resistance-associated substitution mutation. As RBV is associated with a higher risk of treatment-related adverse event, RBV as routine add-on therapy to SOF/VEL should be reconsidered among compensated GT3 cirrhosis patients. |
| Publish Date |
2022-06-23 14:39 |
| Citation |
Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thurairajah PH, Kumar R, Wong YJ. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J Hepatol 2022; 14(6): 1248-1257 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i6/1248.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i6.1248 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
